CoreWeave's Backlog Surge Fails to Lift Guidance, Stock Punished

What happened

CoreWeave's Q1 results showed a 50% Q/Q surge in backlog to $99.4B, but Q2 revenue guidance of $2.45B-$2.6B trailed consensus, underscoring persistent delays in converting signed contracts into recognized revenue. The stock fell 13% on the news, unwinding much of the pre-earnings rally, as the market refocused on the company's stretched commissioning timelines and heavy capital expenditure burden. While the backlog expansion signals strong underlying demand from hyperscalers like Meta and OpenAI, the company cautioned that revenue recognition remains conditional on 'delivery and availability of service requirements,' putting the onus on execution. The updated 10-Q revealed Q1 revenue of $2.08B, up from $982M a year earlier, but net losses widened to $740M as interest expense climbed to $536M. The report confirms the DeepValue thesis that CoreWeave's near-term equity performance hinges on converting its massive backlog into billable capacity—a process still lagging.

Implication

The Q1 print did not break the bull case, but it sharpened the key risk: backlog conversion is slower than the market hoped. The $99.4B backlog is a future asset, but without faster commissioning, revenue growth will remain lumpy and below the $12B-$13B FY2026 guide. The $30B-$35B capex plan requires uninterrupted capital access, and any further guidance disappointment could trigger a re-rating toward the $80 bear case. Meanwhile, the CEO and a 10% owner sold significant shares on May 5, just before the results—a potentially bearish signal. For existing holders, trim above $145; for new buyers, wait for $95 attractive entry or clear Q2 evidence of margin improvement. The next six months are critical to demonstrate that the backlog is not just a nominal figure but a pipeline that can feed revenue growth at a predictable cadence.

Thesis delta

The existing thesis framed CoreWeave as a story of commissioning execution and capital continuity. This quarter's guidance miss does not alter the fundamental thesis—it reinforces it. The delta is that the risk of delayed backlog conversion has moved from a theoretical concern to a demonstrated near-term headwind, increasing the probability of the bear case if Q2 does not show sequential improvement. No shift in rating; the WAIT stance is validated.